Intervention
Oophorectomy
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
2 shownSurgery in Preventing Ovarian Cancer in Patients With Genetic MutationsNCT02760849 · 2016-05-02
ACTIVE_NOT_RECRUITINGSuppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerNCT00066690 · 2003-12-17
COMPLETEDCommon conditions
Deleterious BARD1 Gene Mutation1Deleterious BRCA1 Gene Mutation1Deleterious BRCA2 Gene Mutation1Deleterious BRIP1 Gene Mutation1Deleterious EPCAM Gene Mutation1Deleterious MLH1 Gene Mutation1Deleterious MSH2 Gene Mutation1Deleterious MSH6 Gene Mutation1Deleterious PALB2 Gene Mutation1Deleterious PMS2 Gene Mutation1Deleterious RAD51C Gene Mutation1Deleterious RAD51D Gene Mutation1Estrogen Receptor Positive Breast Cancer1Hereditary Breast and Ovarian Cancer Syndrome1Premenopausal1Progesterone Receptor Positive Tumor1Recurrent Breast Carcinoma1Stage IA Breast Cancer1Stage IB Breast Cancer1Stage IIA Breast Cancer1Stage IIB Breast Cancer1Stage IIIA Breast Cancer1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING1
COMPLETED1
Phase mix
NA1
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.